Global Cerebral Malaria Therapeutics Market by Type (Quinine, Artemisinin Derivatives), By Application (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Drug Store) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
The Global Cerebral Malaria Therapeutics Market size is expected to reach USD 5.4 billion by 2028 from USD 4.6 billion in 2018, growing at a CAGR of 3.8%. The factors such as increasing public awareness about malaria and rising prevalence rates are driving the growth of this market. In addition, increased number of new product launches are fueling the growth prospects of this market globally.
Malaria is a tropical disease caused by the parasite Plasmodium, which can be transmitted through mosquito bites. Symptoms of malaria depend on whether it's been contracted for the first time or if there have already been several infections before and include fever, chills, body aches, headache with vomiting, and diarrhea. Malaria affects more than 200 million people each year causing about 450 000 deaths annually mostly among children in Africa under age five. Malaria prevention methods like the use of bed nets to prevent mosquitoes from biting are available that also provide protection against other diseases such as Zika Virus Disease (ZVD), Dengue Fever (DF), and yellow fever.
On the basis of Type, the market is segmented as Quinine, Artemisinin Derivatives.
Quinine:
Quinine is a naturally occurring substance found in the bark of the cinchona tree. It has been used for centuries to treat malaria, and today it remains an important part of malaria treatment regimens around the world. Quinine works by blocking or inhibiting certain proteins that are needed by malarial parasites within red blood cells to survive.
Artemisinin Derivatives:
Artemisinin Derivatives are a class of drugs derived from the plant Artemisia annua, or sweet wormwood. These compounds have been shown to be highly effective against malaria parasites that harbor resistance to other treatments. Their efficacy is due in part to their ability to inhibit the parasite's production of proteins needed for survival and reproduction inside red blood cells as well as blocking enzymes required for DNA synthesis within malarial parasites.
On the basis of Application, the market is segmented into Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, and Drug Stores. In the retail pharmacy segment, cerebral malaria therapeutics are used for the treatment of cerebral malaria. In this region, quinine has been prescribed by physicians and pharmacists in a high proportion because it’s cheaper than artemisinin derivatives such as Artemether-lumefantrine (Coartem) or Artemisinin-based Combination Therapy (ACT). The use of drugs relies on several factors including availability at lower prices; accessibility to patients; prescriptions from physicians or their relatives. Quinine was also preferred due to its low incidence rates of serious adverse events compared with other available therapies such as ACT.
On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. The cerebral malaria therapeutics market in the Americas is driven by a higher incidence of neurological diseases such as epilepsy or Alzheimer’s disease (AD). North America accounts for the highest market share in the global cerebral malaria therapeutics market followed by Europe trailed by the Asia Pacific. In terms of growth rate, Latin America has shown considerable potential that can be attributed to increasing awareness about health hazards related to this disease among people living there. The Middle East & Africa region occupies a small share owing to high prevalence rates and lack of economic resources required for treatment. The report also covers the current competitive scenario involving key players like Sanofi SE., Bayer AG., Novartis International AG., GlaxoSmithKline plc.
Growth Factors for Global Cerebral Malaria Therapeutics Market:
The growth factors for the global cerebral malaria therapeutics market are as follows:
- Development of new drugs by various research and development institutions, such as Johnson & Johnson.
- Demand in developing countries due to increase in population, particularly Asia Pacific region.
- High incidence rates of cerebral malaria among HIV/AIDS patients with low CDR response rate.
Up Market Research published a new report titled “Cerebral Malaria Therapeutics Market research report which is segmented by Types (Quinine, Artemisinin Derivatives), By Applications (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Drug Store), By Players/Companies Novartis, Cipla, Zydus Cadila, Ipca Laboratories, Sanofi, Eisai”.
Report Scope
Report Attributes | Report Details |
Report Title | Cerebral Malaria Therapeutics Market Research Report |
By Type | Quinine, Artemisinin Derivatives |
By Application | Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Drug Store |
By Companies | Novartis, Cipla, Zydus Cadila, Ipca Laboratories, Sanofi, Eisai |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 205 |
Number of Tables & Figures | 144 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Cerebral Malaria Therapeutics Market Report Segments:
The market is segmented by Type Quinine, Artemisinin Derivatives and By Application Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Drug Store.
Some of the companies that are profiled in this report are:
- Novartis
- Cipla
- Zydus Cadila
- Ipca Laboratories
- Sanofi
- Eisai
Cerebral Malaria Therapeutics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Cerebral Malaria Therapeutics Market
Overview of the regional outlook of the Cerebral Malaria Therapeutics Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Cerebral Malaria Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Cerebral Malaria Therapeutics Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
- By Type:
1. Quinine
2. Artemisinin Derivatives
7. By Application:1. Retail Pharmacies
2. Online Pharmacies
3. Hospital Pharmacies
4. Drug Store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cerebral Malaria Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Cerebral Malaria Therapeutics Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cerebral Malaria Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cerebral Malaria Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cerebral Malaria Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cerebral Malaria Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cerebral Malaria Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Cerebral Malaria Therapeutics Market Size and Y-o-Y Growth
4.5.2 Cerebral Malaria Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Cerebral Malaria Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cerebral Malaria Therapeutics Market Size Forecast by Type
5.2.1 Quinine
5.2.2 Artemisinin Derivatives
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cerebral Malaria Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cerebral Malaria Therapeutics Market Size Forecast by Applications
6.2.1 Retail Pharmacies
6.2.2 Online Pharmacies
6.2.3 Hospital Pharmacies
6.2.4 Drug Store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cerebral Malaria Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cerebral Malaria Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cerebral Malaria Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Cerebral Malaria Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cerebral Malaria Therapeutics Market Size Forecast by Type
9.6.1 Quinine
9.6.2 Artemisinin Derivatives
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cerebral Malaria Therapeutics Market Size Forecast by Applications
9.10.1 Retail Pharmacies
9.10.2 Online Pharmacies
9.10.3 Hospital Pharmacies
9.10.4 Drug Store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cerebral Malaria Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Cerebral Malaria Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cerebral Malaria Therapeutics Market Size Forecast by Type
10.6.1 Quinine
10.6.2 Artemisinin Derivatives
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cerebral Malaria Therapeutics Market Size Forecast by Applications
10.10.1 Retail Pharmacies
10.10.2 Online Pharmacies
10.10.3 Hospital Pharmacies
10.10.4 Drug Store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cerebral Malaria Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cerebral Malaria Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cerebral Malaria Therapeutics Market Size Forecast by Type
11.6.1 Quinine
11.6.2 Artemisinin Derivatives
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cerebral Malaria Therapeutics Market Size Forecast by Applications
11.10.1 Retail Pharmacies
11.10.2 Online Pharmacies
11.10.3 Hospital Pharmacies
11.10.4 Drug Store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cerebral Malaria Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Cerebral Malaria Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cerebral Malaria Therapeutics Market Size Forecast by Type
12.6.1 Quinine
12.6.2 Artemisinin Derivatives
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cerebral Malaria Therapeutics Market Size Forecast by Applications
12.10.1 Retail Pharmacies
12.10.2 Online Pharmacies
12.10.3 Hospital Pharmacies
12.10.4 Drug Store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cerebral Malaria Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cerebral Malaria Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cerebral Malaria Therapeutics Market Size Forecast by Type
13.6.1 Quinine
13.6.2 Artemisinin Derivatives
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cerebral Malaria Therapeutics Market Size Forecast by Applications
13.10.1 Retail Pharmacies
13.10.2 Online Pharmacies
13.10.3 Hospital Pharmacies
13.10.4 Drug Store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cerebral Malaria Therapeutics Market: Competitive Dashboard
14.2 Global Cerebral Malaria Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Cipla
14.3.3 Zydus Cadila
14.3.4 Ipca Laboratories
14.3.5 Sanofi
14.3.6 Eisai